RUBICON ORGANICS INC (ROMJ.CA) Stock Fundamental Analysis
Canada - TSX-V:ROMJ - CA78112W1005 - Common Stock
0.59 CAD
+0.01 (+0.85%)
ROMJ gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 34 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of ROMJ get a neutral evaluation. Nothing too spectacular is happening here. ROMJ is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings would make ROMJ suitable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year ROMJ has reported negative net income.
In the past year ROMJ had a positive cash flow from operations.
ROMJ had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: ROMJ reported negative operating cash flow in multiple years.
1.2 Ratios
ROMJ has a Return On Assets of -1.79%. This is comparable to the rest of the industry: ROMJ outperforms 52.94% of its industry peers.
ROMJ's Return On Equity of -2.64% is fine compared to the rest of the industry. ROMJ outperforms 64.71% of its industry peers.
ROMJ has a better Return On Invested Capital (21.77%) than 100.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ROMJ is significantly above the industry average of 7.75%.
The 3 year average ROIC (19.33%) for ROMJ is below the current ROIC(21.77%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.79% | ||
| ROE | -2.64% | ||
| ROIC | 21.77% |
ROA(3y)-4.91%
ROA(5y)-14.11%
ROE(3y)-7.24%
ROE(5y)-22.2%
ROIC(3y)19.33%
ROIC(5y)N/A
1.3 Margins
ROMJ has a Operating Margin of 26.59%. This is amongst the best in the industry. ROMJ outperforms 100.00% of its industry peers.
With an excellent Gross Margin value of 58.85%, ROMJ belongs to the best of the industry, outperforming 88.24% of the companies in the same industry.
ROMJ's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.59% | ||
| PM (TTM) | N/A | ||
| GM | 58.85% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.88%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ROMJ has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for ROMJ has been increased compared to 1 year ago.
ROMJ has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ROMJ has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.76, we must say that ROMJ is in the distress zone and has some risk of bankruptcy.
ROMJ's Altman-Z score of 1.76 is amongst the best of the industry. ROMJ outperforms 85.29% of its industry peers.
The Debt to FCF ratio of ROMJ is 6.91, which is on the high side as it means it would take ROMJ, 6.91 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 6.91, ROMJ is in the better half of the industry, outperforming 70.59% of the companies in the same industry.
ROMJ has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.22, ROMJ perfoms like the industry average, outperforming 55.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | 6.91 | ||
| Altman-Z | 1.76 |
ROIC/WACC2.21
WACC9.87%
2.3 Liquidity
A Current Ratio of 3.16 indicates that ROMJ has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.16, ROMJ belongs to the top of the industry, outperforming 85.29% of the companies in the same industry.
A Quick Ratio of 1.69 indicates that ROMJ should not have too much problems paying its short term obligations.
With a decent Quick ratio value of 1.69, ROMJ is doing good in the industry, outperforming 67.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.16 | ||
| Quick Ratio | 1.69 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 69.01% over the past year.
ROMJ shows a strong growth in Revenue. In the last year, the Revenue has grown by 29.78%.
Measured over the past years, ROMJ shows a very strong growth in Revenue. The Revenue has been growing by 29.14% on average per year.
EPS 1Y (TTM)69.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.53%
Revenue 1Y (TTM)29.78%
Revenue growth 3Y29.14%
Revenue growth 5YN/A
Sales Q2Q%39.21%
3.2 Future
ROMJ is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 88.99% yearly.
The Revenue is expected to grow by 28.51% on average over the next years. This is a very strong growth
EPS Next Y87.5%
EPS Next 2Y83.71%
EPS Next 3Y88.99%
EPS Next 5YN/A
Revenue Next Year22.82%
Revenue Next 2Y24.16%
Revenue Next 3Y28.51%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ROMJ. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 10.62, the valuation of ROMJ can be described as very reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ROMJ indicates a rather cheap valuation: ROMJ is cheaper than 85.29% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of ROMJ to the average of the S&P500 Index (22.73), we can say ROMJ is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 10.62 |
4.2 Price Multiples
100.00% of the companies in the same industry are more expensive than ROMJ, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, ROMJ is valued a bit cheaper than 70.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 28.24 | ||
| EV/EBITDA | 2.43 |
4.3 Compensation for Growth
ROMJ's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of ROMJ may justify a higher PE ratio.
ROMJ's earnings are expected to grow with 88.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y83.71%
EPS Next 3Y88.99%
5. Dividend
5.1 Amount
No dividends for ROMJ!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:ROMJ (9/12/2025, 7:00:00 PM)
0.59
+0.01 (+0.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners2.9%
Inst Owner ChangeN/A
Ins Owners41.69%
Ins Owner ChangeN/A
Market Cap39.64M
Analysts80
Price Target1.33 (125.42%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)18.18%
PT rev (3m)18.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)92.86%
EPS NY rev (3m)92.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)11.07%
Revenue NY rev (3m)13.63%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 10.62 | ||
| P/S | 0.76 | ||
| P/FCF | 28.24 | ||
| P/OCF | 12.02 | ||
| P/B | 1.05 | ||
| P/tB | 1.13 | ||
| EV/EBITDA | 2.43 |
EPS(TTM)-0.02
EYN/A
EPS(NY)0.06
Fwd EY9.42%
FCF(TTM)0.02
FCFY3.54%
OCF(TTM)0.05
OCFY8.32%
SpS0.78
BVpS0.56
TBVpS0.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.79% | ||
| ROE | -2.64% | ||
| ROCE | 30.24% | ||
| ROIC | 21.77% | ||
| ROICexc | 26.22% | ||
| ROICexgc | 27.97% | ||
| OM | 26.59% | ||
| PM (TTM) | N/A | ||
| GM | 58.85% | ||
| FCFM | 2.69% |
ROA(3y)-4.91%
ROA(5y)-14.11%
ROE(3y)-7.24%
ROE(5y)-22.2%
ROIC(3y)19.33%
ROIC(5y)N/A
ROICexc(3y)24.75%
ROICexc(5y)N/A
ROICexgc(3y)26.66%
ROICexgc(5y)N/A
ROCE(3y)26.85%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.88%
GM growth 5YN/A
F-Score5
Asset Turnover0.94
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | 6.91 | ||
| Debt/EBITDA | 0.48 | ||
| Cap/Depr | 58.09% | ||
| Cap/Sales | 3.63% | ||
| Interest Coverage | 14.7 | ||
| Cash Conversion | 19.24% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.16 | ||
| Quick Ratio | 1.69 | ||
| Altman-Z | 1.76 |
F-Score5
WACC9.87%
ROIC/WACC2.21
Cap/Depr(3y)93.56%
Cap/Depr(5y)171.69%
Cap/Sales(3y)7.51%
Cap/Sales(5y)22.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.53%
EPS Next Y87.5%
EPS Next 2Y83.71%
EPS Next 3Y88.99%
EPS Next 5YN/A
Revenue 1Y (TTM)29.78%
Revenue growth 3Y29.14%
Revenue growth 5YN/A
Sales Q2Q%39.21%
Revenue Next Year22.82%
Revenue Next 2Y24.16%
Revenue Next 3Y28.51%
Revenue Next 5YN/A
EBIT growth 1Y50.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-76.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y510.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.13%
OCF growth 3YN/A
OCF growth 5YN/A